福建三明地区柑橘病毒类病原种类的鉴定及检测

为了明确福建省三明地区柑橘病毒类病原(病毒和类病毒)种类,利用RT-PCR技术对其进行了鉴定和检测,并对其检出率进行了分析。结果表明,从207份柑橘叶片样品中检出柑橘衰退病毒(citrus tristeza virus, CTV)、柑橘黄化脉明病毒(citrus yellow vein clearing virus, CYVCV)、柑橘叶斑驳病毒(citrus leaf blotch virus, CLBV)和蚜虫致死麻痹病毒(aphid lethal paralysis virus, ALPV)等4种病毒以及柑橘曲叶类病毒(citrus bent leaf viroid, CBLVd)、啤酒花矮化类病毒(hop stunt viroid, HSVd)、柑橘矮化类病毒(citrus dwarfing viroid, CDVd)、柑橘类病毒Ⅴ(citrus viroidⅤ, CVdⅤ)和柑橘类病毒Ⅵ(citrus viroidⅥ, CVdⅥ)等5种类病毒。其中,CTV、CYVCV、CLBV和ALPV的检出率分别是71.01%、66.67%、0.97%和6.28%,CBLVd、HSVd、C...     

不同杀菌剂对当归主要病害的防效及经济效益比较

针对甘肃当归病害逐年加重态势, 采用田间随机区组试验, 分析比较70%噁霉灵WP?50%氯溴异氰尿酸WP和80%代森锰锌WP对当归主要病害防效及经济效益, 以期筛选出最佳防控药剂?结果表明:3种杀菌剂均能不同程度防治当归病害, 其中以50%氯溴异氰尿酸WP 1.86 g/L对褐斑病?麻口病防效最佳, 分别为70.38%~78.75%?84.48%~91.04%, 70%噁霉灵WP 0.34 g/L和80%代森锰锌WP 7.92 g/L次之, 对褐斑病防效分别为59.14%~63.72%?58.14%~62.84%, 对麻口病防效分别为78.61%~83.57%?78.97%~83.57%?50%氯溴异氰尿酸WP 1.86 g/L能很好地抑制当归抽薹, 抑制率达58.63%~63.15%?3种杀菌剂均能明显提高当归药材产量构成因子, 以80%代森锰锌WP 7.92 g/L处理增产增收效果最好, 两年平均增产量高达5 559.91 kg/hm2, 平均经济效益为194 136.65元/hm2, 但投入产出比最低, 为1∶480.63?50%氯溴异氰尿酸WP 1.86 g/L对当归病害防效及抽薹抑制率最高, 投入产出比为1∶634.02, 在此基础上综合考虑病害防效和经济效益, 50%氯溴异氰尿酸WP 1.86 g/L可作为生产上防控当归主要病害的主推药剂?     

Hepatitis E virus in Cuba: A cross-sectional serological and virological study in pigs and people occupationally exposed to pigs

Surveillance of hepatitis E virus (HEV) in risk groups is an important strategy to monitor its circulation pattern and to timely detect changes thereof. The aims of this cross-sectional study were to estimate the prevalence of HEV infections in pigs and humans from different regions of the country, to identify risk factors for increasing anti-HEV IgG prevalence and to characterize HEV strains. The presence of anti-HEV antibodies was assessed by commercial ELISA in serum samples from the general population, farm and slaughterhouse employees, as well as pigs sampled in the three regions of Cuba from February to September 2016. Overall, individuals with occupational exposure to swine or swine products (70/248, 28.2%) were 4 times more likely to be seropositive compared to the general population (25/285, 8.7%; OR: 4.18; p < .001). Within the risk group, risk factors included age, number of years working in a professional activity with direct exposure to swine, geographic region and distance between residence and closest professional swine setting, while wearing gloves had a protective effect. Prevalence of total anti-HEV antibodies in swine was 88.2% (165/187) and HEV RNA was detected by real-time RT-PCR in 9.2% (16/173) swine stools. All HEV strains sequenced clustered within genotype 3. Some strains clearly belonged to subtype 3a, while another group of strains was related with subtypes 3b and 3 k but partial HEV sequences did not allow unequivocal subtype assignment. These findings suggest that the high HEV exposure in Cuban individuals with swine-related occupations could be due to enzootic HEV in certain regions, direct contact with infectious animals or their products as well as environmental contamination.     

Tick-borne encephalitis epidemic in Hungary 1951–2021: The story and lessons learned

The authors analysed epidemiological data of the Hungarian tick-borne encephalitis epidemic from the past seven decades. A total of 911 meningitis serosa cases were described from 1930-1950 s by local hospital physicians, indicating that the virus had been present in the country decades before its official identification in 1952. The virus spread freely in the 1950s–1960s, occupying almost all habitats where ticks occurred in large numbers. The increasing number of cases drove authorities to classify this illness as a notifiable disease in 1977 and to organize the first measures to stop the epidemic. Statistical analysis revealed that the large-scale vaccination launched from the 1990s was responsible for the sharp decrease in the number of human cases from 1997. A significant negative correlation was found between the number of vaccine doses sold and human cases 6 years later. The TBEV endemic area covers 16.57% of the territory and 16.65% of the population of the country. In the last 10 years, 186,000 vaccine doses/year in average were enough to keep the incidence of human TBEV infections between 0.45 and 0.06/100,000 persons. A 20-year-long study found evidence for easing clinical signs in TBEV-infected hospitalized patients. Statistics found a sharp decrease in the number of samples sent for TBEV diagnosis after 1989. Male dominance of patients was characteristic of the epidemics since the 1940s, but now analysis of detailed data from the 1981–2021 period (60.5%–87.5%) proved the statistical significance of this dominance. Obviously, the voluntary vaccination programme was the tool which broke the spread of the epidemic. Widespread public awareness of the disease and the tick vector, probable evolutionary spread of less pathogenic virus strains supplemented with the vaccination campaign led to a negligible level of human TBE cases in Hungary in the last years.     

A prospective,randomized, double-blind,placebo-controlled multisite,parallel-group field study in dogs with osteoarthritis conducted in the United States of America evaluating bedinvetmab,a canine anti-nerve growth factor monoclonal antibody

ObjectiveBedinvetmab, a fully canine anti-nerve growth factor monoclonal antibody, was evaluated in dogs for control of osteoarthritis-related pain in a study conducted to support registration in the USA.Study designRandomized, double-blind, placebo-controlled, multicenter, parallel-group study.AnimalsGeneral practice client-owned dogs with osteoarthritis (n = 272).MethodsDogs were block randomized 1:1 to placebo (saline, n = 137) or bedinvetmab (n = 135; 0.5–1.0 mg kg^–1) administered subcutaneously, once monthly. The primary end point, day 28 Canine Brief Pain Inventory (CBPI) treatment success (TS), required pain severity score (PSS; 0–10) decrease ≥1 and pain interference score (PIS; 0–10) decrease ≥ 2. CBPI TS rates [and number needed to treat (NNT)], change in scores [and standardized effect size (ES)], change in quality of life (QoL) and bedinvetmab half-life were calculated.ResultsSignificant (p < 0.05) improvement with bedinvetmab over placebo occurred (days 28, 42, 56, 84) for CBPI TS. Of cases evaluable for day 28 CBPI TS (placebo, n = 131; bedinvetmab, n = 128), success rates were 36.6% and 47.4%, respectively (p = 0.0410) (NNT, 9.3; PSS and PIS ES, 0.3). CBPI TS increased after the second dose in both groups, plateaued for bedinvetmab at day 42 and decreased for placebo beginning day 84. Day 84 NNT (4.3), PSS (0.4) and PIS (0.5) showed continued improvement with monthly dosing. After the first dose, mean (± standard deviation) bedinvetmab half-life was 19.1 (8.3) days. Adverse events were similar between groups and not considered treatment-related. There was a significant effect of bedinvetmab versus placebo on all CBPI components (PIS, PSS, QoL).Conclusions and clinical relevanceThese results corroborated those previously reported and provide further support of safety and effectiveness of bedinvetmab (0.5–1.0 mg kg^–1) administered subcutaneously at monthly intervals to dogs for control of osteoarthritis-related pain.